A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Renaissance Technologies LLC holds 638,133 shares of ACHL stock, worth $625,370. This represents 0.0% of its overall portfolio holdings.

Number of Shares
638,133
Previous 682,734 6.53%
Holding current value
$625,370
Previous $559,000 16.28%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$0.7 - $1.04 $31,220 - $46,385
-44,601 Reduced 6.53%
638,133 $650,000
Q2 2024

Aug 09, 2024

SELL
$0.75 - $1.25 $242,268 - $403,781
-323,025 Reduced 32.12%
682,734 $559,000
Q1 2024

May 13, 2024

BUY
$0.82 - $1.57 $415,546 - $795,619
506,764 Added 101.56%
1,005,759 $1.26 Million
Q4 2023

Feb 13, 2024

BUY
$0.78 - $0.96 $47,944 - $59,008
61,467 Added 14.05%
498,995 $444,000
Q3 2023

Nov 14, 2023

SELL
$0.84 - $1.11 $10,252 - $13,547
-12,205 Reduced 2.71%
437,528 $398,000
Q2 2023

Aug 11, 2023

BUY
$0.82 - $1.09 $56,990 - $75,755
69,500 Added 18.28%
449,733 $425,000
Q1 2023

May 12, 2023

SELL
$0.84 - $1.26 $87,780 - $131,670
-104,500 Reduced 21.56%
380,233 $364,000
Q4 2022

Feb 13, 2023

BUY
$0.79 - $2.39 $318,923 - $964,843
403,700 Added 498.19%
484,733 $436,000
Q3 2022

Nov 14, 2022

SELL
$2.26 - $3.38 $14,011 - $20,956
-6,200 Reduced 7.11%
81,033 $183,000
Q2 2022

Aug 12, 2022

BUY
$1.96 - $3.04 $111,132 - $172,368
56,700 Added 185.7%
87,233 $220,000
Q1 2022

May 13, 2022

BUY
$2.8 - $5.23 $14,000 - $26,150
5,000 Added 19.58%
30,533 $90,000
Q4 2021

Feb 11, 2022

BUY
$4.22 - $8.86 $107,749 - $226,222
25,533 New
25,533 $128,000

Others Institutions Holding ACHL

About Achilles Therapeutics plc


  • Ticker ACHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,774,000
  • Market Cap $40M
  • Description
  • Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...
More about ACHL
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.